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Abstract 
Amyloid-beta peptide (Aβ) has been recognized to interact with numerous proteins, which may lead 
to pathological changes in cell metabolism of Alzheimer’s disease (AD) patients. One such known 
metabolic enzyme is mitochondrial amyloid-binding alcohol dehydrogenase (ABAD), also known as 
17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10). Altered enzyme function caused by the Aβ-
ABAD interaction, was previously shown to cause mitochondrial distress and a consequent cytotoxic 
effect, therefore providing a feasible target in AD drug development. Based on previous frentizole 
derivatives studies, we report two novel series of benzothiazolyl ureas along with novel insights into 
the structure and activity relationships for inhibition of ABAD. Two compounds (37, 39) were 
identified as potent ABAD inhibitors, where compound 39 exhibited comparable cytotoxicity with the 
frentizole standard; however, one-fold higher cytotoxicity than the parent riluzole standard. The 
calculated and experimental physical chemical properties of the most potent compounds showed 
promising features for blood-brain barrier penetration. 
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Alzheimer’s disease (AD) is the most common form of dementia in the elderly, characterized by 
the slow deterioration of cognitive functions.1 The accumulation of amyloid-beta peptide (Aβ) and its 
formation into plaques, along with the formation of neurofibrillary tangles, highlights the 
pathological changes in affected brain regions with progressed AD. These hallmarks have become 
commonly monitored markers, however the initiating events still remain unclear.2 Even though a 
precise mechanism of Aβ-induced toxicity has not been fully understood, several studies have 
reported synaptic and mitochondrial Aβ accumulation and dysfunction in early stages of AD 
development.
2–4
 Furthermore, it has been described that Aβ interacts with various mitochondrial 
proteins, resulting in enhanced oxidative stress, energy misbalance and overall cell toxicity.
2,5–8
 
Amyloid-binding alcohol dehydrogenase (ABAD), also known as 17β-hydroxysteroid 
dehydrogenase type 10 (17β-HSD10), is one of the proteins which was identified to interact directly 
with Aβ at nanomolar concentrations.
9,10
 Moreover, it has been reported that the interaction 
between Aβ and ABAD promotes oxidative stress and mitochondrial dysfunction, consequently 
resulting in cell death.5 Cell based assays and transgenic mice experiments demonstrated that the 
overexpression of both Aβ and ABAD show enhanced cell cytotoxicity, reduced levels of ATP and COX 
activity along with impaired energy metabolism in mice. Conversely, the overexpression of Aβ with 
inactive ABAD displayed less cytotoxicity and transgenic (ABAD) mice when compared with non-
transgenic mice do not display these changes.7,10 Lim et al. reported an ABAD inhibition study where 
the compound (AG18051) appeared to reduce the levels of Aβ-induced oxidative stress and 
mitochondrial respiration impairment, as well as alleviate the Aβ-induced down-regulation of ABAD 
activity.
11
 Whereas elevated levels of ABAD have been associated with AD pathology.
10,12
 Reduced 
levels of ABAD has been reported in brain of Parkinson’s disease patients.
13
 These findings suggest 
that both ABAD-Aβ interaction and ABAD itself may represent a viable objective for deeper 
understanding of AD pathogenesis in context of Aβ-induced toxicity. Consequently, it may also aid in 
the development of novel AD therapeutics. 
There has been a limited number of reported compounds acting as ABAD or ABAD-Aβ interaction 
inhibitors.14,15 In 2006, Xie et al. described the marketed drug frentizole acting as a poor inhibitor of 
ABAD-Aβ interaction (IC50 ~200 µM) along with a novel series of synthesised frentizole analogues 
displaying a 30-fold increase in improved potency (IC50 ~6.5 µM).
16 A more recent study reported two 
phosphonate analogues of these previously discussed compounds, which also exhibited moderate to 
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weak ABAD inhibition (IC50 53 µM and 342 µM).
17,18
 Thus, our aim of the study was focused on 
generating more potent inhibitors based around the benzothiazole scaffold. To this end, a first series 
was designed around a 6-halogen-benzothiazole urea scaffold with various phenyl ring substitution 
patterns including those previously reported (Scheme 1).
16–18
 Furthermore, many benzothiazole 
analogues have been shown to possess various biological activities in the central nervous system.
19
 
Riluzole, a well-known drug with neuroprotective properties, has a similar benzothiazolyl core, 
however its neuroprotective mechanism of action is not still completely understood.
20
 Riluzole is now 
an FDA approved drug to treat amyotrophic lateral sclerosis, and several other studies report riluzole 
exhibiting neuroprotective properties in other neurological disorders (e.g. Parkinson’s disease, 
Huntington’s disease or cerebral ischemia).21–23 Riluzole possesses a wide range of mechanisms of 
action including anti-glutamate activity, Na+ and Ca2+ channel blockage, GABAergic modulation20 
throughout the modulation of the excitatory cascade.24 As Aβ is known to disturb cell ionic 
homeostasis on various levels including calcium balance,25 it can be hypothesized that a riluzole 
moiety may partially mitigate such Aβ-induced ionic homeostasis misbalance. Thus, a second series 
of compounds was designed with a riluzole core moiety and further combined with a urea linker and 
substituted phenyl moiety to more closely address the effect of phenyl ring substitution variations 
(Scheme 1). The urea linker was selected based on compounds that were found to be the most 
potent in perturbing the ABAD-Aβ interaction.
16
 Additionally, the phenyl substitutions were based 
upon the first series of compounds, where oxygen-based substitutions with additional halogen 
substitutions were selected. The second series includes both overlapping substitutions of the first 
compound series (to confirm possible lead structures and validate structure-activity relationship). 
More importantly additional variations of the phenyl ring were made to more exhaustively explore 
possible phenyl ring variations and structure-activity relationship necessary for ABAD inhibition. 
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Scheme 1. Design of benzothiazole-based urea ABAD inhibitors. 
 
While commercially available 6-flouro and 6-chloro substituted benzo[d]thiazole-2-amines were 
used in the first series of compounds, 6-(trifluoromethoxy)benzo[d]thiazol-2-amine (riluzole) was 
prepared from its corresponding para-substituted aniline derivative (Scheme 2). Therefore, 4-
(trifluoromethoxy)aniline was treated with potassium thiocyanate and bromine to afford 6-
(trifluoromethoxy)benzo[d]thiazol-2-amine (1) in excellent yield (94%).26 
 
 
Scheme 2. Synthesis of 4-(trifluoromethoxy)aniline 1. Reagents and conditions: (a) Br2, KSCN, CH3COOH. 
 
Subsequently, two series of benzothiazolyl ureas 5-50 were prepared in a two-step synthesis 
(Scheme 3). Selected 6-subtituted benzo[d]thiazole-2-amines were activated with N,N′-
carbonyldiimidazole to obtain intermediates 2-4 in excellent yields (90-95%), followed by subsequent 
treatment with a substituted aromatic amine
16
 to produce final benzothiazole ureas 5-50 (Table 1) in 
moderate to excellent yields (36-99%). 
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Scheme 3. Synthesis of benzothiazolyl ureas 5-50. Reagents and conditions: (a) CDI, DCM, reflux; (b) Ar-NH2, MeCN, reflux. 
 
A series of compounds (5-50) was screened at 25 µM to determine their ABAD inhibitory ability 
(Table 1) and to show their structure-activity relationship. Within the first series neither frentizole 
nor compounds 5, 6, 11 and 15 (as with previously reported substitutions16–18) showed any 
noteworthy ABAD inhibitory ability. However, compounds 13 and 14 showed a substantial decrease 
(
~
60%) in ABAD activity. Furthermore, compound 12 showed a notable decrease (~20%) in ABAD 
activity. Therefore, selected substitutions were included in the second riluzole-based series with 
additional phenyl ring substitution patterns. The para-hydroxy along meta-chlorine substitution 
patterns proved to display the most pronounced inhibitory activity, where compound 37 showed a 
significant decrease (
~
80%) in ABAD activity. Moreover, the second chlorine in close proximity of the 
phenolic group (39) showed comparable inhibitory activity with compound 37. Therefore, the 
presence of the free phenolic group attached to the distal phenyl ring, is shown to be essential for its 
ability to inhibit ABAD, and the addition of an electron-withdrawing group (such as chlorine) in its 
adjacent proximity greatly increases such an inhibitory ability. Other compounds with a single 
phenolic group (12, 33-35), displacement of 3-chloro-4-hydroxy pattern (36, 38) or isosteric change 
of hydroxyl to thiol group (50) showed a less pronounced drop in ABAD activity (10-30 %). However, 
such a low decrease in enzymatic activity could be accounted by an experimental error. Thus these 
substitution patterns did not provide sufficient SAR information, but they rather indicate the 
presence of weak ABAD inhibition. Interestingly, 3,4-dihydroxy substitution displayed a similarly low 
decrease in enzyme activity (
~
20%). On the other hand, compound 41 revealed an approximately 20% 
increase in ABAD activity, which will be further investigated. Both compounds 37 and 39 
demonstrated a two-fold decrease in ABAD activity when compared to compounds 13 and 14, thus 
underlining that the introduction of a 6-trifluromethoxy moiety instead of a 6-halogen moiety, led to 
an increased inhibitory ability towards ABAD. IC50 values were attempted to be determined for 
compounds 37 and 39, however, this data was unable to be obtained due to the limited solubility of 
these compounds within the enzyme activity assay, and due to the possibility that a biophysical 
effect was observed rather than a true ligand-protein interaction. 
 
Table 1. Prepared benzothiazole ureas (5-50) and their in vitro evaluation. 
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Comp. R
1
 R
2
 
Relative % activity 
remaining @25 µM
1
 
Control - - 100 ± 1.2 
Frentizole OCH3 - 97.9 ± 3.6 
5 F 3-COOMe, 4-OH 97.2 ± 3.8 
6 Cl 3-COOMe, 4-OH 95.6 ± 4.5 
7 F 4-OH 94.4 ± 1.1 
8 Cl 4-OH 91.9 ± 1.9 
9 F 3-OH 94.8 ± 1.0 
10 Cl 3-OH 93.6 ± 1.9 
11 F 2-OH 91.5 ± 1.5 
12 Cl 2-OH 77.1 ± 1.0 
13 F 3-Cl, 4-OH 39.8 ± 0.5 
14 Cl 3-Cl, 4-OH 38.6 ± 0.7 
15 F 3-COOH, 4-OH 101.3 ± 1.6 
16 Cl 3-COOH, 4-OH 100.5 ± 1.1 
17 F 4-OMe 110.9 ± 1.8 
18 Cl 4-OMe 104.6 ± 1.2 
19 F 3,4-OMe 103.6 ± 1.9 
20 Cl 3,4-OMe 104.4 ± 1.5 
21 F 3-COOH, 4-OMe 105.5 ± 1.5 
22 Cl 3-COOH, 4-OMe 107.2 ± 2.5 
23 F 4-OPh 108.8 ± 2.2 
24 Cl 4-OPh 107.4 ± 1.9 
25 F 4-COOH 107.8 ± 1.7 
26 Cl 4-COOH 105.5 ± 1.7 
27 F 4-COOEt 110.3 ± 1.7 
28 Cl 4-COOEt 108.6 ± 2.2 
29 F 4-COOMe 114.7 ± 5.3 
30 Cl 4-COOMe 99.3 ± 3.2 
31 F 4-NHCOMe 94.7 ± 3.3 
32 Cl 4-NHCOMe 97.9 ± 3.4 
33 OCF3 2-OH 92.0 ± 0.1 
34 OCF3 3-OH 78.8 ± 0.1 
35 OCF3 4-OH 69.6 ± 0.1 
36 OCF3 2-Cl, 4-OH 92.0 ± 1.6 
37 OCF3 3-Cl, 4-OH 17.3 ± 0.8 
38 OCF3 2-OH, 4-Cl 65.5 ± 3.0 
39 OCF3 3,5-Cl, 4-OH 20.3 ± 1.1 
40 OCF3 3-Cl, 4-COOH 104.8 ± 2.6 
41 OCF3 2-OH, 4-COOH 119.8 ± 2.1 
42 OCF3 3-OH, 4-COOH 94.8 ± 5.6 
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43 OCF3 3-COOH, 4-OH 96.6 ± 5.5 
44 OCF3 4-OMe 100.7 ± 2.4 
45 OCF3 3-Cl, 4-OMe 91.0 ± 2.6 
46 OCF3 3-OH, 4-OMe 98.3 ± 6.1 
47 OCF3 3,4-OMe 78.9 ± 5.9 
48 OCF3 3-COOH, 4-OMe 86.8 ± 3.0 
49 OCF3 4-COOMe 98.2 ± 1.8 
50 OCF3 2-SH 80.6 ± 5.0 
1
 Relative remaining activity is displayed in percentage of 3 independent measurements ± SEM. 
 
A key aspect in the design of any potential ABAD inhibitors is that they should be CNS 
penetrable. Thus, essential physical chemical properties (HBA, HBD, TPSA, ClogP, ClogD) for efficient 
blood-brain barrier (BBB) penetration were calculated for the two most promising inhibitors 37 and 
39 using ACDLabs PhysChem Suite 2014 (Table 2). The calculated values of the selected physical 
chemical properties either oscillate close to the upper threshold or were found to be slightly higher 
than optimal values proposing CNS bioavailability. Additionally, logP and logD values (further referred 
as ElogP and ElogD) were experimentally determined using adapted OECD guideline.
27
 Both 
calculated values of ClogP and ClogD were found to be in very good agreement with experimental 
data. The presented physical chemical properties of 37 and 39 showed reasonable conformity with 
the requirements for centrally acting compounds28 (based on earlier defined Lipinski rule of five for 
orally administrated drugs).29 Experimental prediction of BBB penetration is further shown in Table 2. 
Data obtained for 37 and 39 are correlated to standard drugs (e.g. donepezil) , where CNS availability 
is known and also reported using the PAMPA assay (Supporting information, Table S1).30 The 
acquired data from the PAMPA assay predicted a possible high BBB penetration for compound 39, 
whereas experimental data for compound 37 estimated a rather uncertain BBB penetration. 
 
Table 2. Physicochemical properties of 37 and 39. 
Comp. Mw HBA/HBD 
TPSA 
(Å2) 
ClogP ± SD1 ELogP ± SD2 ClogD7.4
1
 ELogD7.4 ± SD
2
 Pe ± SEM
3 
Optimal 
LR5 28,29 
≤ 450 ≤ 7 / ≤ 3 ≤ 90 ≤ 5 ≤ 5 0-3 0-3 - 
donepezil 379.49 4/0 38.8 4.23 ± 0.40 --- 2.79 --- 7.3 ± 0.9 
37 403.76 6/3 111.7 4.24 ± 0.41 
4.07 ± 
0.11‰ 
3.35 4.04 ± 2.16‰ 2.2 ± 0.4 
39 438.20 6/3 111.7 5.18 ± 0.43 
4.65 ± 
0.43‰ 
3.79 4.40 ± 2.17‰ 7.0 ± 1.4 
1
 The values were calculated by ACDLabs PhysChem Suite 2014. 
2
 The values refer to experimentally acquired data. 
3
 Prediction of blood-brain barrier penetration of drugs expressed as Pe ± SEM (n = 2-4). High BBB permeation 
predicted for Pe > 4; BBB permeation uncertain for Pe between 2.0 and 4.0; low BBB permeation predicted for 
< 2.0  
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The two most potent compounds (37, 39) were assayed for acute cytotoxicity evaluation 
(Table 3). The compounds’ acute cytotoxicity was determined via a combined MTT and LDH assay 
using CHO-K1 cell lines. A combined cytotoxicity assay was chosen due to the MTT test being partially 
dependent on the mitochondrial oxidoreductases,
31
 whose activity may be influenced by compounds 
targeted to mitochondria. Both MTT and LDH assays for compound 37 showed a greater cytotoxicity 
when compared to frentizole, whereas compound 39 displayed comparable cytotoxicity level with 
frentizole. All evaluated benzothiazolyl ureas (frentizole and compounds 37, 39) showed one order of 
magnitude higher acute cytotoxicity compared to riluzole. In general, the MTT assay data showed a 
trend of a slightly lower IC50 value compared to the LDH data. However, this fact may be caused by 
the compounds’ involvement in the mitochondrial electron transport chain and requires to be 
further elucidated. 
 
Table 3. Acute cytotoxicity evaluation of compound 37 and 39. 
Comp. 
IC50 ± SEM
1(µM) 
MTT CHO-K1 LDH CHO-K1 
frentizole 31 ± 3 46 ± 6 
riluzole 310 ± 33 480 ± 45 
37 7.7 ± 0.7 9.0 ± 1.7 
39 31 ± 5 41 ± 12 
1
 The IC50 value refers to 3 independent measurements ± SEM. 
 
In summary, two novel series of benzothiazolyl ureas were designed and synthesised. All 
compounds were evaluated for ABAD inhibitory ability in vitro, where two riluzole-based compounds 
(37, 39) showed the most promising ABAD inhibitory activity. In terms of the structure-activity 
relationship for the benzothiazole-urea-phenyl scaffold, the combination of a 4-phenolic moiety with 
a chlorine in its close proximity was confirmed to be essential for compounds ABAD inhibitory ability 
(13, 14, 37, 39). Possible good BBB permeation was predicted for compound 39 by experimental 
determination, and the cytotoxicity of compound 39 was also found to be similar to the frentizole 
standard, but was one order of magnitude higher to its parent compound riluzole. Overall the most 
promising compounds (37 and 39) exhibited solubility issues within the activity assay and were 
predicted with at least a borderline BBB penetration. 
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